drugset
Drugs / BOOST cells
last change Jun 2024 re-read 3 minutes ago

BOOST cells

Cell therapy

Developed for
osteogenesis imperfecta
Investigated by
Karolinska Institutet · Christian Medical College, Vellore, India · Great Ormond Street Hospital for Children NHS Foundation Trust · Karolinska University Hospital · Leiden University Medical Center · Lund University
+5 more · Ministry of Science and Technology, India · UMC Utrecht · University College, London · University Hospital Cologne · Vinnova

Trials 2

today NCT03706482 · Ph 1/2 NCT04623606 · Ph 1/2
20202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03706482 Aug 2019 → Apr 2030 expected osteogenesis imperfecta Karolinska Institutet Active not recruiting No outcome recorded
Phase 1/2 NCT04623606 May 2019 → Nov 2021 osteogenesis imperfecta Christian Medical College, Vellore, India Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BOOST cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04623606 ↗
1

NCT03706482 ↗
Modality Cell therapy “expanded human 1st trimester fetal liver-derived mesenchymal stem cells” NCT04623606 ↗
Route Intravenous “Each subject receives four intravenous doses of 3×106/kg BOOST cells at 4 month intervals” PMID 38834319 ↗ Jun 2024